Leypoldt John K, Burkart John M
Research Service, Salt Lake City VA Health Care System, Departments of Internal Medicine and Bioengineering, University of Utah, Salt Lake City, Utah, USA.
Adv Perit Dial. 2002;18:26-31.
Previous theoretic and clinical studies have shown that continuous flow peritoneal dialysis (CFPD) provides a high dose of small-solute removal; however, the dose of middle-molecule removal with CFPD therapy has not been evaluated. We used a variable-volume, two-compartment model to calculate theoretical steady-state solute kinetic profiles during CFPD, continuous ambulatory peritoneal dialysis (CAPD), and hemodialysis using a high-flux dialyzer (HFHD), for an anuric 70-kg patient and two measures of dose: equivalent renal clearance (EKR) and standard Kt/V (stdKt/V). Dose measures during each therapy were calculated for five solutes: urea, creatinine, vitamin B12, inulin, and beta 2-microglobulin. Fluid (1 L daily) was assumed to accumulate in and to be removed from the extracellular space, and non renal clearance was assumed to be zero for all solutes except beta 2-microglobulin. Calculated doses for CFPD were higher than for CAPD or HFHD when assessed by either EKR or stdKt/V. Dose enhancements for CFPD were highest for small solutes, but were still considerable for middle molecules. We conclude that CFPD achieves higher doses than CAPD or HFHD for both small-solute and middle-molecule removal.
以往的理论和临床研究表明,持续性非卧床腹膜透析(CFPD)能大量清除小分子溶质;然而,CFPD治疗中大分子溶质的清除量尚未得到评估。我们采用可变容积双室模型,计算了一名70kg无尿患者在CFPD、持续性非卧床腹膜透析(CAPD)和高通量血液透析(HFHD)过程中的理论稳态溶质动力学曲线,并采用两种剂量衡量指标:等效肾清除率(EKR)和标准Kt/V(stdKt/V)。针对尿素、肌酐、维生素B12、菊粉和β2-微球蛋白这五种溶质,计算了每种治疗方式下的剂量指标。假设每天有1L液体在细胞外液中蓄积并被清除,除β2-微球蛋白外,所有溶质的非肾清除率均假设为零。当通过EKR或stdKt/V评估时,CFPD的计算剂量高于CAPD或HFHD。CFPD对小分子溶质的剂量增加最高,但对大分子溶质仍相当可观。我们得出结论,CFPD在清除小分子溶质和大分子溶质方面比CAPD或HFHD实现了更高的剂量。